Journal Article

FZJ-2024-03242

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology

Blömeke, L.FZJ* ; Rehn, F.FZJ* ; Kraemer-Schulien, V.FZJ* ; Kutzsche, J.FZJ* ; Pils, M.FZJ* ; Bujnicki, T.FZJ* ; Lewczuk, P. ; Kornhuber, J. ; Freiesleben, S. D. ; Schneider, L.-S. ; Preis, L. ; Priller, J. ; Spruth, E. J. ; Altenstein, S. ; Lohse, A. ; Schneider, A. ; Fliessbach, K. ; Wiltfang, J. ; Hansen, N. ; Rostamzadeh, A. ; Düzel, E. ; Glanz, W. ; Incesoy, E. I. ; Butryn, M. ; Buerger, K. ; Janowitz, D. ; Ewers, M. ; Perneczky, R. ; Rauchmann, B.-S. ; Teipel, S. ; Kilimann, I. ; Goerss, D. ; Laske, C. ; Munk, M. H. ; Sanzenbacher, C. ; Spottke, A. ; Roy-Kluth, N. ; Heneka, M. T. ; Brosseron, F. ; Wagner, M. ; Wolfsgruber, S. ; Kleineidam, L. ; Stark, M. ; Schmid, M. ; Jessen, F. ; Bannach, O. (Corresponding author)FZJ* ; Willbold, D. (Corresponding author)FZJ* ; Peters, O. (Corresponding author)

2024
Wiley Hoboken, NJ

This record in other databases:      

Please use a persistent id in citations: doi:10.1002/dad2.12589  doi:10.34734/FZJ-2024-03242

Abstract: INTRODUCTION: Soluble amyloid beta (Aβ) oligomers have been suggested as initiating Aβ related neuropathologic change in Alzheimer’s disease (AD) but their quantitative distribution and chronological sequence within the AD continuum remain unclear.METHODS: A total of 526 participants in early clinical stages of AD and controls from a longitudinal cohort were neurobiologically classified for amyloid and tau pathology applying the AT(N) system. Aβ and tau oligomers in the quantified cerebrospinal fluid (CSF) were measured using surface-based fluorescence intensity distribution analysis (sFIDA) technology.RESULTS: Across groups, highest Aβ oligomer levels were found in A+ with subjective cognitive decline and mild cognitive impairment.Aβ oligomers were significantly higher in A+T− compared to A−T− and A+T+. APOE ε4 allele carriers showed significantly higher Aβ oligomer levels. No differences in tau oligomers were detected.DISCUSSION: The accumulation of Aβ oligomers in the CSF peaks early within the AD continuum, preceding tau pathology. Disease-modifying treatments targeting Aβ oligomers might have the highest therapeutic effect in these disease stages.

---

Contributing Institute(s):

1. Strukturbiochemie (IBI-7)

Research Program(s):

1. 5244 - Information Processing in Neuronal Networks (POF4-524) (POF4-524)

Appears in the scientific report 2024

---

Database coverage:
; ; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Emerging Sources Citation Index ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Web of Science Core Collection

---